A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study Following Intravenous Administration of HF1K16 in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of HF1K16
Latest Information Update: 27 May 2024
At a glance
- Drugs Tretinoin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors HighField Biopharmaceuticals
- 21 May 2024 Status changed from discontinued to completed.
- 30 May 2022 New trial record